Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Egypt / NCT07668011
Recruiting Not applicable

Radial Extracorporeal Shockwave Therapy in Individuals With Iliotibial Band Syndrome

NCT07668011 · tracked via the Priya Life Science Egypt tracker
Sponsor
Cairo University
Phase
Not applicable
Started
2026-06-10
Last updated
2026-06-25

Condition(s) studied

Iliotibial Band Syndrome

Investigational drug(s) / intervention(s)

Standard ITBS Exercise ProgramRadial Extracorporeal Shockwave TherapySham Extracorporal Shockwave Therapy

Standard ITBS Exercise Program: Standard ITBS Exercise Program : Flexibility and Strengthening Exercises will be delivered three times weekly over a 4-week period

Radial Extracorporeal Shockwave Therapy: Radial Extracorporeal Shockwave Therapy will be delivered once weekly for 4 weeks only.

Sham Extracorporal Shockwave Therapy: Sham Extracorporal Shockwave therapy will be administered once a week for 4 weeks.

Study summary

The goal of this Clinical Trial Study is to evaluate the clinical effectiveness of Radial Electrocorporeal Shockwave Therapy (rESWT) combined with exercise in individuals with iliotibial band syndrome (ITBS).The main question it aims to answer is : Does the addition of rESWT to standard ITBS exercise program reduce pain intensity and pain pressure threshold while improving lower extremity function and hip muscle strength in Individuals with Iliotibial Band syndrome (ITBS). Participants will be divided into two groups to be compared : The ShamTherapy Group (Control Group) that will receive the standard ITBS exercise program in addition to Sham rESWT, while the experimental group will receive the standard ITBS exercise program in addition to Radial Extracorporeal Shockwave Therapy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
No
Inclusion Criteria: * Physically active individuals aged 18 and 45 years * Have a clinical diagnosis of iliotibial band syndrome (ITBS) confirmed by physician within the previous four weeks. * Report lateral knee pain during running or other functional activities * No history of direct trauma * Have a positive Noble compression or/and Ober test. Exclusion Criteria: * History of knee surgery,fracture , meniscal or ligamentous injury within the past year * Any fracture involving the lower extremity within the previous six months * Neurological disorders * Lumbar radiculopathy * Systemic inflammatory disease * Any medical condition affecting gat or lower extremity function. * Have received corticosteroid injection, shockwave therapy, or physical therapy treatment for ITBS within the previous six months * Use of NDAID's or analgesics later than 2 weeks * Individuals with contraindications to ESWT, including pregnancy, bleeding disorders, or use of anticoagulant medication.

Primary outcome measure(s)

  • Numerical Pain Rating Scale Score (NPRS) — baseline , immediately after the 4-week intervention period ( post intervention ) ,4 weeks after the intervention cessation as follow-up.
    To assess lateral knee pain intensity at rest and during activity Scores range from 0 (no pain) to 10 (worst pain)

Trial sites (1)

FacilityCityRegionStatus
Cairo University Hospitals Giza Giza Governorate Recruiting

More Cairo University trials in Egypt

The Link Between Periodontitis, Smoking and Oral Cancer Starting soon
Treating Intrabony Defect With MINST VS MINST Extended PRF Recruiting
Respiratory Exercises Versus Deep Neck Flexor Training in Chronic Mechanical Neck Pain Recruiting
Integrating Aerobic, Respiratory, and Cognitive Training in Acute Heart Failure Starting soon
Preparation Time Of Bioflx Crowns Compared To Zirconia Crowns On Primary Molars Starting soon

Other trials for the same condition

Neuromuscular Inhibition Technique on Iliotibial Band Friction Syndrome Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07668011 on ClinicalTrials.gov ↗ ← All trials in Egypt